Allogene Therapeutics Inc.

35.76-0.5400-1.49%Vol 372.41K1Y Perf 22.81%
Oct 26th, 2020 16:00 DELAYED
BID34.62 ASK37.46
Open35.80 Previous Close36.30
Pre-Market- After-Market-
 - -%  - -%
Target Price
50.70 
Analyst Rating
Moderate Buy 1.63
Potential %
41.78 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-100/-81/-85 
Value Ranking
 —    -
Insiders Value % 3/6/12 mo.
-100/-15/-18 
Growth Ranking
 —    -
Insiders Shares Cnt. % 3/6/12 mo.
-100/-24/-29 
Income Ranking
 —    -
Market Cap4.98B 
Earnings Rating
Buy
Price Range Ratio 52W %
48.79 
Earnings Date
3rd Nov 2020

Today's Price Range

35.2436.51

52W Range

17.4355.00

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-7.47%
1 Month
4.37%
3 Months
-5.89%
6 Months
22.64%
1 Year
22.81%
3 Years
-
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
ALLO35.76-0.5400-1.49
AAPL115.050.01000.01
GOOG1 590.45-50.5500-3.08
MSFT210.08-6.1500-2.84
XOM33.35-0.8100-2.37
WFC22.70-0.5800-2.49
JNJ143.97-1.2700-0.87
FB277.11-7.6800-2.70
GE7.38-0.2500-3.28
JPM101.24-2.5700-2.48
Earnings HistoryEstimateReportedSurprise %
Q02 2020-0.55-0.533.64
Q01 2020-0.57-0.5012.28
Q04 2019-0.69-0.5815.94
Q03 2019-0.54-0.507.41
Q02 2019-0.47-0.4112.77
Q01 2019-0.41-0.3221.95
Q04 2018-0.23-0.35-52.17
----
Earnings Per EndEstimateRevision %Trend
9/2020 QR-0.555.17Positive
12/2020 QR-0.603.23Positive
12/2020 FY-2.164.85Positive
12/2021 FY-2.465.38Positive
Next Report Date3rd Nov 2020
Estimated EPS Next Report-0.55
Estimates Count9
EPS Growth Next 5 Years %-
Volume Overview
Volume372.41K
Shares Outstanding139.29M
Trades Count4.45K
Dollar Volume13.94M
Avg. Volume810.85K
Avg. Weekly Volume430.04K
Avg. Monthly Volume544.60K
Avg. Quarterly Volume586.50K

Allogene Therapeutics Inc. (NASDAQ: ALLO) stock closed at 36.3 per share at the end of the most recent trading day (a 2.72% change compared to the prior day closing price) with a volume of 455.81K shares and market capitalization of 4.98B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 190 people. Allogene Therapeutics Inc. CEO is David D. Chang.

The one-year performance of Allogene Therapeutics Inc. stock is 22.81%, while year-to-date (YTD) performance is 39.72%. ALLO stock has a five-year performance of %. Its 52-week range is between 17.43 and 55, which gives ALLO stock a 52-week price range ratio of 48.79%

Allogene Therapeutics Inc. currently has a PE ratio of -, a price-to-book (PB) ratio of 4.70, a price-to-sale (PS) ratio of -, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -22.81%, a ROC of -25.28% and a ROE of -24.98%. The company’s profit margin is -%, its EBITDA margin is -%, and its revenue ttm is $0.00 , which makes it $0.00 revenue per share.

Of the last four earnings reports from Allogene Therapeutics Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.55 for the next earnings report. Allogene Therapeutics Inc.’s next earnings report date is 03rd Nov 2020.

The consensus rating of Wall Street analysts for Allogene Therapeutics Inc. is Moderate Buy (1.63), with a target price of $50.7, which is +41.78% compared to the current price. The earnings rating for Allogene Therapeutics Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Allogene Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Allogene Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 18.25, ATR14 : 1.97, CCI20 : -90.91, Chaikin Money Flow : 0.12, MACD : -0.16, Money Flow Index : 64.20, ROC : -10.26, RSI : 44.96, STOCH (14,3) : 19.14, STOCH RSI : 0.46, UO : 38.35, Williams %R : -80.86), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Allogene Therapeutics Inc. in the last 12-months were: Alison Moore (Option Excercise at a value of $313 812), Alison Moore (Sold 128 162 shares of value $5 163 562 ), Arie S. Belldegrun (Buy at a value of $6 879 954), David D. Chang (Sold 20 335 shares of value $392 615 ), Eric Schmidt (Sold 35 450 shares of value $1 244 445 ), Rafael Amado (Sold 16 538 shares of value $651 515 ), Veer Bhavnagri (Option Excercise at a value of $136 200), Veer Bhavnagri (Sold 66 553 shares of value $2 448 087 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
11 (68.75 %)
10 (62.50 %)
9 (60.00 %)
Moderate Buy
0 (0.00 %)
1 (6.25 %)
1 (6.67 %)
Hold
5 (31.25 %)
5 (31.25 %)
5 (33.33 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.63
Moderate Buy
1.69
Moderate Buy
1.73

Allogene Therapeutics Inc.

Allogene Therapeutics Inc is the United States-based clinical stage immuno-oncology company. It is mainly engaged in the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The company is involved in developing a pipeline of multiple allogeneic T cell product candidates utilizing validated gene editing and advanced proprietary cell manufacturing technologies. Its pipeline includes UCART19 which is developed for the treatment of relapsed or refractory acute lymphoblastic leukemia (ALL), as well as several preclinical allogeneic CAR T therapies.

CEO: David D. Chang

Teplephone: +1 650 457-2700

Address: 210 East Grand Avenue, South San Francisco 94080, CA, USA

Number of employees: 190

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

53%47%

Bearish Bullish

58%42%

Bearish Bullish

58%42%

News

Stocktwits